 VolitionRx NYSE-A:VNRX Ltd has struck an exclusive 28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the formers Nu.Q vet cancer screening test at the point-of-care for pets. Heska will receive the worldwide rights to sell the test while VolitionRx NYSE-A:VNRX will get a 10 million upfront payment on signing and up to 18 million based upon near to mid-term milestones. 